Arcus Biosciences (RCUS) Free Cash Flow Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 88.70% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 66.37% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.98% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 137.65% |
| 10 | Arcus Biosciences | 3.18 Bn | 2.36 Bn | - | -3.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.76% |
| Dec 31, 2025 | -17.82% |
| Sep 30, 2025 | -488.00% |
| Jun 30, 2025 | -37.11% |
| Mar 31, 2025 | -4,333.33% |
| Dec 31, 2024 | -40.28% |
| Sep 30, 2024 | 134.25% |
| Jun 30, 2024 | -56.45% |
| Mar 31, 2024 | 97.03% |
| Dec 31, 2023 | -2.86% |
| Sep 30, 2023 | 12.05% |
| Jun 30, 2023 | 8.82% |
| Mar 31, 2023 | -115.47% |
| Dec 31, 2022 | -54.32% |
| Sep 30, 2022 | -28.01% |
| Jun 30, 2022 | 12.48% |
| Mar 31, 2022 | 1,045.01% |
| Dec 31, 2021 | 14.10% |
| Sep 30, 2021 | -130.00% |
| Jun 30, 2021 | -225.93% |
| Mar 31, 2021 | -119.46% |
| Dec 31, 2020 | -458.78% |
| Sep 30, 2020 | 923.26% |
| Jun 30, 2020 | -15.99% |
| Mar 31, 2020 | -82.86% |
| Dec 31, 2019 | 12.07% |
| Sep 30, 2019 | -141.72% |
| Jun 30, 2019 | -83.68% |
| Mar 31, 2019 | -23.50% |
| Dec 31, 2018 | -206.45% |
| Sep 30, 2018 | 54.29% |
| Jun 30, 2018 | -80.18% |
| Mar 31, 2018 | -30.34% |